Sibutramine safety under international review

摘要

Medicines regulatory agencies in Europe and the US are reviewing the safety profile of sibutramine (Reductil) after a preliminary analysis of data from a recent trial suggested a possible increased risk of serious cardiovascular events. Sibutramine is already contraindicated in patients with a history of cardiovascular disease.